AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 04, 2021

New FDA approvals mean new treatment options for dermatology

Experts discuss recently approved drugs for the treatment of systemic conditions with cutaneous manifestations, as well as side effects.


Vinod Nambudiri, MD, MBA, FAAD
Vinod Nambudiri, MD, MBA, FAAD

The FDA is working overtime — not just on review of COVID-19 vaccines and therapies — but on a host of other new drug approvals. Notably, many new drugs offer new treatment options for dermatologic diseases. Friday’s session, “New Medications in the New Normal” (U008) scans the list of new drugs and their potential impact on dermatology.

The pandemic didn’t slow the FDA’s efforts to complete 53 novel drug approvals in 2020 and another 25 during the first half of 2021. According to session director Vinod Nambudiri, MD, MBA, FAAD, associate physician in the department of dermatology at Brigham and Women’s Hospital, this session will spotlight those recently approved drugs for the treatment of systemic conditions with cutaneous manifestations (such as acne, Chagas disease, neurofibromatosis type 1, and progeria), as well as medications with cutaneous side effects.

“Several of these agents are medications that have implications for the management of dermatologic conditions, including medications for the treatment of neurofibromatosis, head lice, acne, and actinic keratoses,” Dr. Nambudiri said.

Upon review of the new therapies, Dr. Nambudiri said, dermatologists will be able to identify the mechanism and indications for each new medication, cite its relevance to dermatology, and recognize specific cutaneous effects of these novel therapeutics.

For example, clascoterone is a newly approved topical cream for the management of acne. It acts as a topical androgen receptor inhibitor. Although systemic agents with hormonal mechanisms such as oral contraceptives and spironolactone have been available for decades, this drug represents a new tool for dermatologists to offer patients with hormone-sensitive acne, he said. 

Another agent, tirbanibulin, is a recently approved treatment for actinic keratoses. It responds through inhibition of microtubules at the cellular level to stop precancerous lesions from proliferating. Given the increasing rates of skin cancer and the aging population, Dr. Nambudiri said having additional treatments for the management of actinic keratoses represents an advance for managing neoplastic growths.

Of course, there are other patient considerations, even if the drugs have received approval, including the patient’s out-of-pocket expense and the full scope of the drug’s efficacy, Dr. Nambudiri said.

“As new medications are emerging, it’s important for dermatologists to familiarize themselves not only with their use and effects, but also their costs and limitations,” he said. “This session will attempt to address these factors for a variety of new therapeutics in dermatology to help dermatologists make informed decisions with their patients.”

 

Interesting Stories
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.